MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Quote | MorphoSys AG (NASDAQ:MOR)
Last: | $19.34 |
---|---|
Change Percent: | -1.78% |
Open: | $18.83 |
Close: | $19.34 |
High: | $19.5 |
Low: | $18.8 |
Volume: | 948,095 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | MorphoSys AG (NASDAQ:MOR)
2024-05-16 15:08:23 ET More on MorphoSys MorphoSys: Hold Rating Until The Novartis Deal Closes MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript MorphoSys reports Q1 results New safety risk for MorphoSys drug could complicate Novartis deal - STAT (update) ...
2024-04-30 20:36:07 ET Summary MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A tr...
Message Board Posts | MorphoSys AG (NASDAQ:MOR)
Subject | By | Source | When |
---|---|---|---|
News: $MOR MorphoSys Announces That Its Patents Were | whytestocks | investorshub | 01/26/2019 7:46:16 PM |
Molycor Adds Magnesium Product Specialist To Advisory Committee | abriana90 | investorshub | 01/17/2012 1:32:48 PM |
Molycor Adds Power Consultant To Advisory Committee | abriana90 | investorshub | 01/11/2012 1:54:22 PM |
New web site up and running Looks Great | abriana90 | investorshub | 12/21/2011 3:11:49 PM |
Did you set up this board with the | CleanForMePlease | investorshub | 12/10/2011 3:57:44 AM |
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG Company Name:
MOR Stock Symbol:
NASDAQ Market:
2024-04-30 06:15:05 ET Oddo BHF analyst issues NEUTRAL recommendation for MOR on April 30, 2024 04:35AM ET. MOR was trading at $17.36 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold, 1 -...
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. My...
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – S...